NYSE: KVUE
Kenvue Inc. describes itself as the world's largest pure-play consumer health company by revenue. It was separated from former parent Johnson & Johnson. The company reports three segments:
- **Self Care:** pain care with Tylenol and Motrin, digestive health with Pepcid, and smoking cessation with Nicorette.
- **Skin Health and Beauty:** Neutrogena, Aveeno, and hair care brands Rogaine and OGX.
- **Essential Health:** baby care with Johnson's Baby, women's health with Stayfree and o.b., wound care with BAND-AID Brand, and oral care with Listerine.
Kenvue sells its science-backed, healthcare-professional-recommended products through retail and e-commerce channels across North America, EMEA, Asia Pacific and Latin America. North America is its largest region. The company is executing its 2026 Restructuring Initiative to optimize its operating model and supply chain. It is also nearing completion of a pending combination with Kimberly-Clark. Updated
Kenvue is going quiet, skipping guidance and the conference call with the Kimberly-Clark combination near completion, leaving a fourth straight quarter of sales growth to speak for itself. Revenue beat estimates and adjusted earnings came in just under expectations, with a 29.4% effective tax rate weighing on results.
Wall Street holds or sells every one of these four blue chips, yet each has raised its dividend every single year and yields at least 4.35%. Find out why the analyst skepticism…
Four household names spread across pipelines, tobacco, banking, and consumer staples are paying yields that most blue chips never come close to, but a big yield number means nothing if the cash…
Jim Cramer called Kimberly-Clark hated, but the real story behind its dividend streak, its free cash flow, and a social media disinformation campaign in China raises harder questions than Cramer let on.
Johnson and Johnson has raised its dividend every single year for 64 years straight, yet a plain S&P 500 index fund still beat it handily over the past decade. Understanding why reveals…
Both Kimberly-Clark and Clorox are mid-overhaul, both pay yields above 4.5%, and both have dividend payout ratios that leave almost no cushion. When two consumer staples giants look this similar on paper,…
Kimberly-Clark has raised its dividend for over five decades, but a looming $48 billion acquisition and razor-thin cash flow coverage are putting that streak under pressure most income investors haven't noticed yet.
While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and…
One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind…
Kimberly-Clark just logged its 54th straight year of dividend increases, but a shrinking raise, falling free cash flow, and a massive acquisition in progress raise a pointed question for income investors living…
Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.
Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%. The problem sits right next…
While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.
Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can…
Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this…
Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist…
Kenvue Inc. describes itself as the world's largest pure-play consumer health company by revenue. It was separated from former parent Johnson & Johnson.
24/7 Wall St.'s 12-month price target for KVUE is $21.87, rated Buy. The Wall Street consensus target is $19.50. KVUE price prediction →
